Compare Stocks: FDMT, AGIO, BHVN, and SLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$30.69 +2.2%	$34.48	$22.24 ▼ $46.00	$1.83B	0.58	1.06 million shs	609,948 shs
BHVN Biohaven	$13.39 -0.8%	$13.60	$7.48 ▼ $18.57	$2.02B	1.28	2.61 million shs	860,261 shs
FDMT 4D Molecular Therapeutics	$9.98 -2.0%	$10.58	$5.11 ▼ $14.00	$522.08M	2.7	799,963 shs	174,450 shs
SLS SELLAS Life Sciences Group	$10.87 +8.6%	$10.60	$1.39 ▼ $15.88	$2.14B	2.42	8.41 million shs	3.95 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	-17.44%	-20.12%	+6.61%	-14.23%
BHVN Biohaven	0.00%	-5.81%	-15.29%	+40.12%	-8.64%
FDMT 4D Molecular Therapeutics	0.00%	+1.09%	-21.69%	+11.99%	+58.57%
SLS SELLAS Life Sciences Group	0.00%	-11.57%	-33.18%	+103.04%	+503.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$30.69 +2.2%	$34.48	$22.24 ▼ $46.00	$1.83B	0.58	1.06 million shs	609,948 shs
BHVN Biohaven	$13.39 -0.8%	$13.60	$7.48 ▼ $18.57	$2.02B	1.28	2.61 million shs	860,261 shs
FDMT 4D Molecular Therapeutics	$9.98 -2.0%	$10.58	$5.11 ▼ $14.00	$522.08M	2.7	799,963 shs	174,450 shs
SLS SELLAS Life Sciences Group	$10.87 +8.6%	$10.60	$1.39 ▼ $15.88	$2.14B	2.42	8.41 million shs	3.95 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	-17.44%	-20.12%	+6.61%	-14.23%
BHVN Biohaven	0.00%	-5.81%	-15.29%	+40.12%	-8.64%
FDMT 4D Molecular Therapeutics	0.00%	+1.09%	-21.69%	+11.99%	+58.57%
SLS SELLAS Life Sciences Group	0.00%	-11.57%	-33.18%	+103.04%	+503.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.40	Hold	$40.88	35.54% Upside
BHVN Biohaven	2.67	Moderate Buy	$21.63	59.92% Upside
FDMT 4D Molecular Therapeutics	2.80	Moderate Buy	$30.67	205.44% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-6.70% Downside

Current Analyst Ratings Breakdown

Latest FDMT, AGIO, BHVN, and SLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	AGIO Agios Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $52.00
7/31/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$41.00 ➝ $39.00
7/31/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$37.00
7/30/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $55.00
7/28/2026	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$54.00 ➝ $52.00
7/20/2026	FDMT 4D Molecular Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
7/17/2026	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SLS SELLAS Life Sciences Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	AGIO Agios Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$28.00 ➝ $32.00
7/7/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $41.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$54.03M	33.32	N/A	N/A	$20.46 per share	1.47
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
FDMT 4D Molecular Therapeutics	$88.24M	5.95	N/A	N/A	$8.85 per share	1.13
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	N/A
BHVN Biohaven	-$738.82M	-$5.67	N/A	N/A	N/A	N/A	-866.46%	-137.99%	8/10/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.57	N/A	N/A	N/A	-182.34%	-36.83%	-32.55%	8/10/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.23	N/A	N/A	N/A	N/A	-47.12%	-42.63%	8/6/2026 (Estimated)

Latest FDMT, AGIO, BHVN, and SLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	N/A	N/A	N/A	$0.49 million	N/A
8/10/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.04	N/A	N/A	N/A	$3.62 million	N/A
8/6/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	N/A	N/A	N/A	N/A	N/A
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million
5/12/2026	Q1 2026	SLS SELLAS Life Sciences Group	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
5/7/2026	Q1 2026	FDMT 4D Molecular Therapeutics	-$0.97	-$1.01	-$0.04	-$1.01	$2.59 million	$3.05 million
5/4/2026	Q1 2026	BHVN Biohaven	-$0.86	-$0.88	-$0.02	-$0.88	$0.27 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
BHVN Biohaven	1.87	7.41	7.41
FDMT 4D Molecular Therapeutics	N/A	9.34	9.34
SLS SELLAS Life Sciences Group	N/A	17.22	17.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
BHVN Biohaven	88.78%
FDMT 4D Molecular Therapeutics	99.27%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
BHVN Biohaven	13.80%
FDMT 4D Molecular Therapeutics	7.90%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	59.70 million	56.48 million	Optionable
BHVN Biohaven	239	150.56 million	129.78 million	Optionable
FDMT 4D Molecular Therapeutics	120	52.28 million	48.15 million	Optionable
SLS SELLAS Life Sciences Group	10	196.63 million	194.08 million	Not Optionable

FDMT, AGIO, BHVN, and SLS Headlines

Recent News About These Companies

SLS stock eyes green start to August after nearly $6M in fresh institutional buying: Retail stays bearish

August 3 at 6:52 AM | msn.com

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst

August 2 at 11:00 AM | seekingalpha.com

SELLAS Life Sciences Group (SLS) Projected to Announce Earnings on Thursday

August 1 at 2:26 AM | americanbankingnews.com

SELLAS Life Sciences Group (SLS) Expected to Release Quarterly Earnings on Thursday

August 1 at 2:25 AM | marketbeat.com

SLS stock in spotlight after Vanguard Capital discloses 5.19% stake – retail calls it 'huge vote of conviction' as AML trial readout nears

July 31 at 11:11 PM | msn.com

SLS stock turns green after 3-day rout: Five investors add shares as key AML trial nears final trigger

July 31 at 1:10 PM | msn.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 12.5% - Should You Sell?

July 28, 2026 | marketbeat.com

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

July 28, 2026 | marketbeat.com

SLS Stock Hits 1-Month Low On China Arbitration Blow — Retail Bulls Call It A ‘Nothingburger’ Ahead Of AML Readout

July 28, 2026 | finance.yahoo.com

3D prevails in arbitration against Sellas, awarded $1M in costs

July 27, 2026 | msn.com

SLS stock climbs premarket: Here’s what smart money is doing as Sellas nears critical phase 3 AML readout

July 27, 2026 | msn.com

Sellas CEO Angelos Stergiou says '100% certain' AI can be used to beat cancer

July 24, 2026 | msn.com

SLS stock rises overnight: Retail traders call new AML survival data 'huge' ahead of CEO’s Fox appearance

July 24, 2026 | msn.com

SLS stock July rout deepens: 'Pharma Bro' Martin Shkreli questions timing of AML trial, says data may wait until Christmas

July 23, 2026 | msn.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 6.3% - What's Next?

July 22, 2026 | marketbeat.com

SLS stock tracks worst month since March: Investor slashes stake by over 30% as quiet period begins ahead of AML readout

July 22, 2026 | msn.com

SLS stock rises overnight: Retail thinks CEO just dropped buyout clues ahead of Fox appearance

July 21, 2026 | msn.com

SLS stock hits July low as AML readout nears — retail bulls see 'stellar' hint in CEO's Fox appearance next week

July 18, 2026 | msn.com

SELLAS Life Sciences Group (SLS) Stock Looks Rich On Book Value Yet Strong On Returns

July 18, 2026 | finance.yahoo.com

SELLAS Life Sciences rebounds 12% as investors continue to wait for key data

July 18, 2026 | seekingalpha.com

SELLAS Life Sciences Group (SLS) Stock Pricey Following Phase 3 Trial Buzz

July 18, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FDMT, AGIO, BHVN, and SLS Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$30.69 +0.67 (+2.24%)

As of 02:44 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Biohaven NYSE:BHVN

$13.39 -0.11 (-0.79%)

As of 02:44 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

4D Molecular Therapeutics NASDAQ:FDMT

$9.98 -0.21 (-2.01%)

As of 02:44 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

SELLAS Life Sciences Group NASDAQ:SLS

$10.87 +0.86 (+8.57%)

As of 02:44 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FDMT, AGIO, BHVN, and SLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FDMT, AGIO, BHVN, and SLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FDMT, AGIO, BHVN, and SLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FDMT, AGIO, BHVN, and SLS Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Biohaven NYSE:BHVN

4D Molecular Therapeutics NASDAQ:FDMT

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FDMT, AGIO, BHVN, and SLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FDMT, AGIO, BHVN, and SLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FDMT, AGIO, BHVN, and SLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FDMT, AGIO, BHVN, and SLS Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Biohaven NYSE:BHVN

4D Molecular Therapeutics NASDAQ:FDMT

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools